PNC-27 Research Guide

Full name: PNC-27 (p53-Derived Anticancer Peptide)

An experimental peptide derived from the p53 tumor suppressor protein, studied for selectively destroying cancer cells. It remains preclinical and is included for educational reference; it is not an approved therapy.

How PNC-27 Works

Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies.

Dosing Protocol

• Typical dose: Not established for humans
• Frequency: Research only
• Duration: Research only
• Route: Injection (research)

Reported Benefits

• Selective cancer-cell targeting (preclinical)
• p53/HDM-2 mechanism of interest
• Reported sparing of normal cells (studies)

Potential Side Effects

• Unknown human safety
• No approved human use
• Unproven efficacy in humans

Research Citations

1. PNC-27 selective cancer cell necrosis (2010) - Reported to selectively induce necrosis of cancer cells via membrane HDM-2 binding while sparing normal cells in preclinical models.

Related Detox & Antioxidant Compounds

• Glutathione (IV/IM) - Full Profile
• NAC - Full Profile
• EDTA Chelation - Full Profile
• Activated Charcoal - Full Profile
• PQQ - Full Profile
• TUDCA - Full Profile

View full PNC-27 profile with 3D molecule viewer →